
Journal of Medicinal Chemistry

Opioid Peptidomimetics: Leads for the Design of Bioavailable Mixed Efficacy μ Opioid Receptor (MOR) Agonist/ δ Opioid Receptor (DOR) Antagonist Ligands

Henry I. Mosberg,^{*,†,‡} Larisa Yeomans,[†] Aubrie A. Harland,[‡] Aaron M. Bender,[‡] Katarzyna Sobczyk-Kojiro,[†] Jessica P. Anand,[‡] Mary J. Clark,[§] Emily M. Jutkiewicz,[§] and John R. Traynor[§]

[†]Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States [‡]Interdepartmental Program in Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States [§]Department of Pharmacology, Medical School, University of Michigan, Ann Arbor, Michigan 48109, United States

ABSTRACT: We have previously described opioid peptidomimetic, **1**, employing a tetrahydroquinoline scaffold and modeled on a series of cyclic tetrapeptide opioid agonists. We have recently described modifications to these peptides that confer a μ opioid receptor (MOR) agonist, δ opioid receptor (DOR) antagonist profile, which has been shown to reduce the development of tolerance to the analgesic actions of MOR agonists. Several such bifunctional ligands have been reported, but none has been demonstrated to cross the blood-brain barrier. Here we describe the transfer of structural features that



evoked MOR agonist/DOR antagonist behavior in the cyclic peptides to the tetrahydroquinoline scaffold and show that the resulting peptidomimetics maintain the desired pharmacological profile. Further, the 4*R* diastereomer of 1 was fully efficacious and approximately equipotent to morphine in the mouse warm water tail withdrawal assay following intraperitoneal administration and thus a promising lead for the development of opioid analgesics with reduced tolerance.

INTRODUCTION

The recognition that the simultaneous modulation of multiple targets may generate a more desirable drug profile has challenged the long prevailing, intuitive bias toward selectively targeted drugs as the optimal approach for the discovery and development of new therapeutics (for recent reviews see refs 1–3). This concept is exemplified in the field of opioid analgesics by the observation that coadministration of a μ opioid receptor (MOR) agonist with a δ opioid receptor (DOR) antagonist retains MOR-mediated analgesia but displays reduced development of tolerance and dependence,^{4–6} features that limit the clinical use of opioid analgesics.

For pharmacokinetic simplicity it is preferable to incorporate all desired activities into a single compound, and the development of bifunctional opioid ligands has thus become a topic of increasing interest. For many years, our focus had been on receptor selective opioids. While structure—activity efforts toward this aim were quite successful, a number of "failures" (including ligands that displayed high affinity for both MOR and DOR) resulted and were not pursued further. The subsequent accumulation of convincing evidence for the value of MOR agonist/DOR antagonist ligands encouraged us to reinvestigate our earlier nonselective peptides. This reinvestigation led to the development of a cyclic tetrapeptide Tyrc(SEtS)[D-Cys-Aic-D-Pen]OH (KSK103),⁷ where Aic is 2aminoindane-2-carboxylic acid, Pen is penicillamine, and c(SEtS) designates cyclization through the D-Cys and D-Pen side chain sulfurs as an ethylene dithioether. This peptide exhibits high affinity for MOR and DOR (and low affinity for the κ opioid receptor, KOR) and is a MOR agonist/DOR antagonist.⁷ Follow-up studies⁸ revealed that steric bulk and conformational constraint of the Aic or similar substitutions were key factors for achieving in vitro MOR agonism/DOR antagonism in this series.

Other peptide,⁹ peptide-like,^{10,11} and non-peptide¹² structures have been reported that display MOR agonist/DOR antagonist profiles; however, none of these have demonstrated centrally mediated in vivo activity after peripheral administration. This poor bioavailability is typical of peptides, and while several approaches have been demonstrated to improve peptide penetration of biological membranes,^{13–15} the alternative strategy of incorporating the key pharmacophore elements of a peptide with desired pharmacological properties into a more druglike scaffold provides a more direct strategy toward improved bioavailability. The main hurdle that must be cleared in the latter approach is ensuring that the resulting peptidomimetic does indeed demonstrate the desired pharmacological profile.

We have previously described the peptidomimetic diastereomeric pair of 1, designed to incorporate the key opioid pharmacophore elements of the parent tetrapeptide Tyr-

Received:January 10, 2013Published:February 18, 2013

c(SS)[D-Cys-Phe-D-Pen]OH, 2 (JOM-13,¹⁶ Figure 1), and related cyclic tetrapeptides, namely, a tyramine moiety and a





Figure 1. (A) Structure of lead peptide 2 (JOM-13, Tyr-c(SS)[p-Cys-Phe-p-Pen]OH). (B) Structure of lead peptidomimetic 1(4*R*). (C) Superposition of proposed bioactive conformations of JOM-13 and 1(4*R*) (see ref 16).

second aromatic group, attached to a tetrahydroquinoline (THQ) scaffold.¹⁶ This design strategy proved to be successful, as the higher affinity diastereomer of 1 displayed high binding affinity to MOR, DOR, and KOR.¹⁴ Our observation that Aic and other replacements for Phe in cyclic peptides related to 2 confer a MOR agonist/DOR antagonist profile suggested that 1 might be a promising starting point for the development of related peptidomimetics with similar profiles but with improved bioavailability compared to the peptides. Here we establish that the higher affinity diastereomer of 1 is the 4R diastereomer (1(4R)) and demonstrate that (a) 1(4R) displays a promising in vitro profile with high MOR efficacy and low DOR efficacy, (b) 1(4R) is approximately equipotent to morphine in the antinociceptive mouse warm water tail withdrawal assay after intraperitoneal administration, thus showing great promise as a lead for the development of a bioavailable MOR agonist/DOR antagonist, and (c) modifications that confer high MOR efficacy/low DOR efficacy in our cyclic peptide series retain this effect when used as replacements for the benzyl pendant on the THQ scaffold of 1.

RESULTS

Synthesis of 1. Our original synthesis of 1 yielded the 4*R* and 4*S* diastereomeric pair, which were easily separated by RP-HPLC and pharmacologically evaluated individually, with the observation that the diastereomer that elutes earlier on HPLC displays 5- to 10-fold higher binding affinity at MOR, DOR, and KOR than the later eluting diastereomer. In order to confirm the stereochemistry of 1, we undertook an asymmetric synthesis (Scheme 1). Briefly, ketone intermediate 3 was Boc protected to give 4, which was reduced with the (*S*)-methyl-CBS catalyst¹⁷ to give chiral, 4*R* alcohol 5 in 80% ee, similar to previous reports for analogous scaffolds.^{17,18} The secondary chiral alcohol was then converted to an amine, with complete inversion of stereochemistry via a Mitsunobu reaction,¹⁹ yielding chiral, 4*S* amine 7 to which di-Boc protected 2,6-dimethyl-L-tyrosine (Boc-Dmt) was coupled. After deprotec-

Scheme 1. Asymmetric Synthesis of Compound 7^a



"Reagents and conditions: (a) (Boc)₂O, DMAP, DIEA, DCM, reflux; (b) (S)-2-methyl-CBS-oxazoborolidine, BH₃·Me₂S, THF; (c) phthalimide, DIAD, PPh₃, THF; (d) N₂H₄·H₂O, EtOH.

tion of this unequivocal 4S diastereomer, HPLC revealed a 9:1 ratio of late eluting to early eluting diastereomer of 1, confirming that the late eluting diastereomer is 4S and the (higher affinity) early eluting diastereomer is 4R, depicted in Figure 1.

Opioid Receptor Binding and Efficacy. Binding affinities (K_i) (obtained by competitive displacement of radiolabeled [³H]diprenorphine in C6 cells stably expressing MOR or DOR or CHO cells stably expressing KOR, as previously described^{20,21}) for both diastereomers of **1** and efficacy (assessed by agonist-stimulated [³⁵S] GTP γ S binding in the same cells²²) at MOR, DOR, and KOR of the higher affinity 4*R* diastereomer are shown in Tables 1 and 2, respectively. As

Table 1. Opioid Receptor Binding Affinities of Peptidomimetics a

	binding, K _i (nM)					
compd	MOR	DOR	KOR			
$1(4R)^{b}$	0.22 ± 0.02	9.4 ± 0.8	68 ± 2			
15a	0.24 ± 0.02	8.9 ± 1.5	25 ± 1			
15b	0.76 ± 0.14	6.0 ± 0.7	17 ± 1			
15c	0.078 ± 0.007	10 ± 2	54 ± 7			
15d	0.16 ± 0.04	4.1 ± 1.6	1.2 ± 0.4			
morphine ^c	6.3 ± 2.5	171 ± 18.9	60.9 ± 17.3			
$1(4S)^{b}$	2.6 ± 0.3	56 ± 5	220 ± 48			
15a'	16 ± 2.6	120 ± 15	1200 ± 290			
15c′	1.6 ± 0.4	66 ± 1	130 ± 9			
15ď	8.0 ± 0.8	180 ± 14	110 ± 9			

^{*a*}Binding affinities (K_i) were obtained by competitive displacement of radiolabeled [³H]diprenorphine in membrane preparations. All values are expressed as the mean \pm SEM of three separate assays performed in duplicate. ^{*b*}From ref 16. ^{*c*}From ref 36.

shown in Table 1, the now confirmed 4*R* diastereomer of 1 displays very high MOR affinity and is approximately 40- and 300-fold selective for MOR vs DOR or KOR, respectively. The 4*S* diastereomer shows significantly lower affinity, especially at MOR. As seen in Table 2, the 4*R* diastereomer of 1 shows high MOR potency and efficacy in the stimulation of GTP γ S binding assay. Consistent with the binding data, the potency of 1(4*R*) is

Table 2. Opioid	Receptor	Efficacy of	f Peptic	lomimetics"
-----------------	----------	-------------	----------	-------------

	EC ₅₀ (nM)			% stimulation		
compd	MOR	DOR	KOR	MOR	DOR	KOR
1 (4 <i>R</i>)	1.6 ± 0.3	110 ± 6	540 ± 72	81 ± 2	16 ± 2	22 ± 2
15a	1.1 ± 0.3	dns	dns	45 ± 5	dns	dns
15b	0.84 ± 0.35	69 ± 35	dns	93 ± 5	15 ± 1	dns
15c	0.53 ± 0.08	dns	dns	96 ± 3	dns	dns
15d	0.24 ± 0.03	dns	68 ± 15	86 ± 1	dns	38 ± 2
morphine ^b	194 ± 21	nt	nt	57 ± 5		

^{*a*}Efficacy data were obtained using agonist induced stimulation of $[^{35}S]$ GTP γ S binding assay. Efficacy is represented as EC₅₀ (nM) and percent maximal stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 μ M. All values are expressed as the mean \pm SEM of three separate assays performed in duplicate. dns: does not stimulate. nt: not tested. ^{*b*}From ref 7.

much lower at DOR and KOR. Of special interest is the observation that 1(4R) is a partial agonist at DOR and KOR, displaying only 16% and 22% maximal stimulation compared to the standards DPDPE and U69,593, respectively, suggesting a very promising starting point for the development of MOR agonist/DOR antagonist analogues.

Since, as described above, other MOR agonist/DOR antagonist ligands have been reported, the promise of THQ scaffold peptidomimetics like 1 is dependent on the ability of compounds in such a series to display centrally mediated effects after peripheral administration, a property not yet demonstrated for other MOR agonist/DOR antagonist ligands. Thus, we examined the antinociceptive activity of the lead compound 1(4R) in the mouse warm water tail withdrawal (WWTW) antinociception assay²³ following intraperitoneal (ip) administration.

The dose-response curve for 1(4R) in the WWTW assay is presented in Figure 2 which shows that 1(4R) produces a dose




Figure 2. Antinociceptive activity of 1(4R) in mouse warm water tail withdrawal (WWTW) assay following intraperitoneal (ip) administration. Data represent response following pretreatment (-30 min) with saline (open circles) or naltrexone (NTX, filled circles) given by ip injection.

dependent increase in tail withdrawal latency (up to the 20 s cutoff) with an $ED_{50} \approx 3 \text{ mg/kg}$ (~6 $\mu \text{mol/kg}$). Figure 2 further shows that this antinociceptive effect is opioid receptor mediated, since the opioid antagonist naltrexone at 1 mg/kg ip produces a rightward shift in the dose/response curve of 1(4*R*). The time course of the antinociceptive activity of 1(4*R*) in the WWTW assay, along with that for morphine, is shown in Figure 3. As seen there, 1(4*R*) displays a rapid onset of effect and maximal antinociception is maintained for approximately




Figure 3. Time-course of antinociception (WWTW assay) of 1(4R) (filled squares) and morphine (open circles) following ip administration.

60 min followed by a slow decline. The duration of action of 1(4R) is somewhat shorter than that of morphine.

Encouraged by the antinociceptive activity and bioavailability of 1(4R), we prepared a small series of analogues in which the benzyl side chain of 1 was replaced by bulkier or more constrained aromatic moieties. These replacements were based on results we had obtained in the tetrapeptide and pentapeptide series developed from 2. Using computational models of active and inactive states of MOR and DOR,^{7,8} we predicted and confirmed that replacing the Phe³ residue in these tetra- or pentapeptides with a bulkier or more constrained aromatic residue would maintain MOR efficacy but reduce DOR efficacy. In particular, 1-naphthylalanine (1-Nal), 2naphthylalanine (2-Nal), and 2-aminoindane-2-carboxylic acid (Aic), substitution for Phe all resulted in analogues that displayed MOR agonist/DOR antagonist behavior and maintained high affinity binding to both receptors.^{7,8,24} Since peptidomimetic 1 was designed from 2 (Figure 1), we examined the effect of transferring the corresponding modifications to the THQ scaffold of 1 in place of the benzyl moiety (Figure 4), anticipating that, as in the peptide series, MOR agonist/DOR antagonist profiles would be observed.

Synthesis of Peptidomimetic Analogues of 1. Compounds 8a,b were prepared by P_2O_5 -catalyzed Friedel–Crafts acylation of benzene or naphthalene with the corresponding *p*nitrocarboxylic acid (Scheme 2).²⁵ 8b was synthesized as a mixture of the 1-naphthalene and 2-naphthalene products in a 1:4 ratio. 8c was prepared by Suzuki coupling²⁶ between 2naphthaleneboronic acid and *p*-nitrobenzyl bromide, and 8d was prepared by an aldol condensation between 1-indanone and *p*-nitrobenzoic acid. The resulting nitro compounds were





Figure 4. Structures of peptidomimetics.

Scheme 2. Preparation of Compounds $9a-d^a$





^{*a*}Reagents and conditions: (a) benzene or naphthalene, P_2O_5 , Al_2O_3 , reflux; (b) 2-naphthalenylboronic acid, $PdCl_2$, K_2CO_3 , acetone, H_2O , 110 °C, microwave irradiation; (c) 1-indanone, KOH, MeOH; (d) 10% Pd/C, H_2 , HCl, MeOH.

subjected to hydrogenation to afford amines 9a-d, which were then acylated with 3-bromopropionyl chloride to afford 10a-d. Cyclization with NaOtBu formed the four-membered lactams (11a-d), which were then rearranged under Fries conditions to give dihydroquinolinones 12a-d.²⁷ Oxime formation (13a-d) and subsequent hydrogenation gave racemic primary amines 14a-d, which could then be coupled to Boc-Dmt under standard peptide coupling conditions (Scheme 3).

The synthetic protocol described in Schemes 2 and 3 yields racemic mixtures of 4R and 4S scaffolds which are then used to generate the diastereomeric pairs of final peptidomimetics 15aand 15a', 15c and 15c', and 15d and 15d'. The diastereomer of 15b was observed but an insufficient amount for testing was isolated. In each pair, the "unprimed" number (15a-d)represents the diastereomer that elutes earlier in RP-HPLC, which in all cases is also the higher affinity diastereomer, as discussed below.

As was observed in our original report of 1,¹⁶ the earlier eluting diastereomer of each tested pair displays 1-2 orders of magnitude higher MOR and DOR affinity compared with the later eluting diastereomer. Since the structural modifications within the series are rather minor and confined to the pendent





"Reagents and conditions: (a) 3-bromopropionyl chloride, K_2CO_3 , DCM; (b) NaOtBu, DMF; (c) TfOH, DCE; (d) NH₂OH·HCl, NaOAc, EtOH, H₂O, reflux; (e) 10% Pd/C, H₂, AcOH, MeOH; (f) Boc-Dmt, PyBOP, HOBt-Cl, DIEA, DMF; (g) TFA, DCM.

moiety on the THQ scaffold, it is very likely that the higher affinity diastereomer in each of the new analogues is, as was observed for 1, the 4R diastereomer. This would, of course, need to be confirmed for any analogue chosen for extensive in vivo testing.

As seen in Table 1, all peptidomimetics bind with highest affinity at MOR (by a factor of 8-130) and, except for the diastereomeric pair 15d and 15d', all slightly prefer DOR over KOR. Efficacy data for the higher affinity diastereomers 1(4R)and 15a-d are summarized in Table 2 as both EC₅₀ and percent maximal stimulation compared to the standard agonists DAMGO, DPDPE, and U69,593 for MOR, DOR, and KOR, respectively. With the exception of 15a, all the peptidomimetics tested display high efficacy at MOR and all are very potent, with EC_{50} values of ~1 nM. By contrast, none of these ligands significantly stimulate DOR, consistent with the desired MOR agonist/DOR antagonist profile, and only 15d displays significant agonist properties at KOR. To confirm the desired MOR agonist/DOR antagonist profile, the ability of 15c, a representative example from the series, to antagonize the stimulation of GTP γ S binding evoked by the DOR agonist DPDPE was assessed. As expected, compound 15c acted as a DOR antagonist, producing a rightward shift in the stimulation curve of DPDPE at DOR with $K_e = 34.3 \pm 2.7$ nM, in good agreement with the observed binding K_i of 10 nM for 15c at DOR.

DISCUSSION AND CONCLUSIONS

Two results obtained with 1(4R) are particularly noteworthy. First, the demonstration that this peptidomimetic modeled on a full agonist peptide displays high MOR efficacy but low DOR efficacy establishes it as strong lead for the development of MOR agonist/DOR antagonists using the THQ scaffold. The low DOR efficacy of 1(4R) is consistent with our previously described models of interactions of opioid ligands with active and inactive states of the receptors.^{7,8} The binding pocket in the region of the Phe³ side chain of the tetrapeptide 2 and the benzyl substituent of the THQ scaffold of 1(4R) (Figure 1C) includes Asn¹²⁵, Thr²¹⁸, and Lys³⁰³ in MOR and the corresponding, bulkier Lys¹⁰⁸, Met¹⁹⁹, and Trp²⁵⁴ in DOR. The inactive state of both receptors can accommodate benzyl and even bulkier substituents; however, these bulkier substituents clash with the larger residues of DOR in the more compact binding pocket found in the active state of the receptor, reducing efficacy at this receptor. As seen in the overlay of 1(4R) with 2 in Figure 1C, the phenyl ring of 1(4R) (red) extends farther (deeper into the DOR pocket) giving rise to its greater steric clash with the DOR active state and hence its reduced DOR efficacy compared to 2.

The second critical observation for 1(4R) is its promising bioavailability. As shown in Figures 2 and 3, 1(4R) displays antinociceptive activity in the mouse WWTW assay after ip administration and with similar potency as morphine. To date, no MOR agonist/DOR antagonist ligands have been reported that display central activity after peripheral administration; hence, this represents a key result and promising lead.

The data in Tables 1 and 2 support the promise of this peptidomimetic series, as they demonstrate that features that confer DOR antagonism in our recently reported peptides^{7,8,24} act similarly in the peptidomimetic series described here. For example, the 2-methylnaphthyl substituted **15c** reduces DOR efficacy compared to the 1-methylnaphthyl analogue **15b**. This mirrors observations made in the peptide series.⁸ While all the peptidomimetics examined display low DOR efficacy, it appears that modifications with longer extended R (**15a**, **15c**, **15d** in Figure 1) are less compatible with the DOR active state. This is consistent with the observed low DOR efficacy of **1**(4*R*) compared with its DOR full agonist peptide counterpart **2** discussed above.

Compounds 15a-d, like 1(4R), are the higher affinity (and earlier eluting on HPLC) diastereomers of each pair and, given the structural similarity to 1, most likely share the 4R stereochemistry that was unequivocally determined for 1(4R). Compounds 15a-d all display fairly similar pharmacological profiles, with 15c exhibiting the most promising combination of high MOR efficacy and potency, potent DOR antagonism, and somewhat reduced affinity (and no efficacy) at KOR. Compound 15d displays a slightly different profile from the other members of the series in its considerably higher KOR affinity and smaller range of affinities across the three receptors. It also exhibits a potentially interesting MOR agonist/KOR partial agonist profile, a profile that may be useful for combating cocaine dependence.^{28–30} Preliminary inspection of peptidomimetic docking to our receptor models suggests that the indanyl of 15d can interact favorably with Val¹⁰⁸ of transmembrane helix 2 (TM2) of the active conformation of KOR while the corresponding R substituent of the other peptidomimetics either adopt alternative low energy conformations or sterically clash with this region of the active state of KOR. Hence, 15d displays both higher KOR affinity and efficacy than the other analogues described here.

While the peptidomimetics described here show promise, their profiles require optimization before moving forward to in vivo tolerance studies. For example, the preferred MOR agonist/DOR antagonist ligand would display similar, high affinity for MOR and DOR, translating into potent, high efficacy MOR agonism and potent DOR antagonism while interacting poorly with KOR. These preliminary results do, however, provide strong support for our structure-based design approach employing our ligand—receptor models and also lend confidence to our plans to further employ the THQ scaffold, which allows favorable interactions with MOR, DOR, and KOR, to "tune" the pharmacological profile by incorporating modifications that exploit differences in nearby residues of MOR, DOR, and KOR in order to more closely equalize MOR and DOR binding affinity and reduce KOR affinity.

Finally, a MOR agonist/DOR antagonist profile is not unique in being associated with reduced development of tolerance and other MOR agonist side effects. Several groups have described positive results with ligands that act as a MOR agonist/DOR agonist.^{31–34} Included among these are ligands that are active after peripheral administration.^{31–33} It is unclear whether DOR agonists and DOR antagonists exert their effects on MOR agonists in similar ways. For example, we showed that coadministration of a DOR agonist potentiates the potency and efficacy of morphine even in mice rendered tolerant to morphine.³⁵ Thus, it is possible that the reported reduction in MOR tolerance effected by DOR agonists reflects this potentiation of MOR agonist potency and/or efficacy.

EXPERIMENTAL SECTION

Chemistry. All reagents and solvents were obtained from commercial sources and used without additional purification. To prepare P₂O₅/Al₂O₃ (w/w 50%), Al₂O₃ was placed in an oven at 120 °C for 24 h. After it reached room temperature in a desiccator, P₂O₅ was added in equal amounts. The compounds were mixed and returned to the desiccator for later use. Suzuki couplings were performed on a Discover S-class (CEM) microwave in a closed vessel with maximum power input of 300 W and temperature set at 110 °C for 10 min under the standard method from their Synergy software. Hydrogenations were performed on a Parr hydrogenator apparatus from Parr Instrument Company, model 3916EA, at the pressures specified using 10% Pd/C as the catalyst. Flash column chromatography was carried out using P60 silica gel (230-400 mesh). Purification of final compounds was performed using a Waters semipreparative HPLC with a Vydac protein and peptide C₁₈ reverse phase column, using a linear gradient of 15% solvent B (0.1% TFA in acetonitrile) in solvent A (0.1% TFA in water) to 50% solvent B in solvent A at a rate of either 0.5% or 1% per minute and monitoring UV absorbance at 230 nm. Purity of synthesized compounds was determined on a Waters Alliance 2690 analytical HPLC instrument and a Vydac protein and peptide C_{18} reverse phase column, using a linear gradient of 0% solvent B in solvent A to 45%, 70%, or 90% solvent B in solvent A in 45, 70, or 90 min, respectively, and UV absorbance at 230 nm (gradient A). Purities of the final compounds used for testing were ≥95% as determined by HPLC. ¹H NMR and ¹³C NMR data were obtained on either a 400 or 500 MHz Varian spectrometer using CDCl₃ or CD₃OD solvents. The identity of each compound was verified by mass spectrometry using an Agilent 6130 LC-MS mass spectrometer in positive mode.

General Procedure A for (S)-2-Amino-N-((S)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6dimethylphenyl)propanamide (1). The amine intermediate 7 (121 mg, 0.358 mmol) was dissolved in DMF (5 mL) followed by the addition of the coupling reagents PyBOP (186 mg, 0.358 mmol), HOBt-Cl (70.0 mg, 0.358 mmol), and DIEA (624 µL, 3.58 mmol). Boc-DMT (146 mg, 0.358 mmol) was dissolved in DMF (5 mL) and added to the reaction mixture, which was stirred for 18 h at room temperature. After concentration under reduced pressure the product was resuspended in EA (30 mL) and washed with a solution of 5% citric acid in H₂O (30 mL). The aqueous layer was then extracted with EA (10 mL), and the combined organic extracts were washed with brine (1 \times 10 mL), dried with MgSO₄, filtered, and concentrated under reduced pressure. The crude residue was dissolved in a 1:1 mixture of DCM and TFA (10 mL) and stirred for 3 h. The mixture was concentrated and purified by semipreparative HPLC to yield the title compound in a 9:1 ratio of diastereomers. HPLC (gradient A): retention time = 25.50 (early), 28.85 (late). EI-MS 452.2 $[M + Na]^+$ for both diastereomers.

Synthesis of Compounds 4-7. tert-Butyl 6-Benzyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (4). Compound 3¹⁶ (2.57 g, 10.8 mmol) was dissolved in DCM (70 mL), followed by the addition of (Boc)₂O (3.06 g, 14.1 mmol), DMAP (132 mg, 1.08 mmol), and DIEA (2.45 mL, 14.1 mmol). The mixture was stirred at reflux for 35 h, after which time it was quenched with 1 M HCl (50 mL). The aqueous layer was extracted with DCM. The combined organic extracts were dried with MgSO4, filtered, and concentrated, and the residue was chromatographed on silica gel (1:2 EA/hex) to yield the title compound as a white solid (2.79 g, 77%). Rf (50% EA/ hex): 0.71. ¹H NMR (400 MHz, CDCl₃) δ 7.83 (d, J = 1.6, 1H), 7.69 (d, J = 1.6, 1H), 7.29 (dd, J = 8.6, 1.9, 1H), 7.26-7.19 (m, 2H), 7.18-7.10 (m, 3H), 4.08 (t, J = 6.2, 2H), 3.90 (s, 2H), 2.68 (t, J = 6.3, 2H), 1.53 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 194.23, 152.74, 142.37, 140.39, 134.61, 128.80, 128.54, 127.14, 126.26, 124.78, 123.81, 82.07, 44.26, 41.14, 38.97, 28.27.

(R)-tert-Butyl 6-Benzyl-4-hydroxy-3,4-dihydroquinoline-1(2H)-carboxylate (5). Compound 4 (2.69 g, 7.97 mmol) was dissolved in THF (30 mL) and stirred at room temperature with 4 Å molecular sieves (1.0 g) for 1 h. This solution was transferred to the (S)-(-)-2-methyl-CBS-oxazaborolidine catalyst via cannula, and the reaction vessel was cooled to -20 °C. BH₃·Me₂S (3.99 mL, 7.97 mmol) was then added via syringe over a period of 10 min. The mixture was stirred at -20 °C for 6 h. After the addition of MeOH (7 mL) the mixture was allowed to reach room temperature. The mixture was partitioned between 1 M HCl (10 mL) and Et₂O (30 mL). The aqueous layer was extracted with Et₂O (3×20 mL). The combined organic extracts were washed with brine (20 mL), dried with MgSO₄, filtered, and concentrated, and the residue was chromatographed on silica gel (1:2 EA/hex) to yield the title compound as a colorless oil (2.19 g, 81%, 80% ee). R_f (50% EA/hex): 0.48. ¹H NMR (400 MHz, $CDCl_3$) δ 7.72 (d, J = 8.5, 1H), 7.30–7.14 (m, 6H), 7.08 (dd, J = 8.16, 1.6, 1H), 4.53 (t, J = 4.8, 1H), 3.92 (s, 2H), 3.53 (ddd, J = 13.1, 9.5, 3.8, 1H), 3.40 (s, 1H), 1.98-1.90 (m, 1H), 1.89-1.79 (m, 1H), 1.56 (s, 9H); $^{13}\mathrm{C}$ NMR (101 MHz, CDCl₃) δ 153.73, 141.15, 136.11, 135.71, 131.04, 128.92, 128.49, 128.25, 126.10, 123.57, 81.08, 65.47, 41.33, 40.74, 32.13, 28.43. Enantioselectivity determined by HPLC (Chiracel OD-RH column, 45% acetonitrile/water, 230 nm, 25 °C): $t_{\rm major} = 21.3 \text{ min}, t_{\rm minor} = 25.2 \text{ min}.$

(S)-tert-Butyl 6-Benzyl-4-(1,3-dioxoisoindolin-2-yl)-3,4-dihydroquinoline-1(2H)-carboxylate (6). Compound 5 (2.12 g, 6.27 mmol) was dissolved in THF (25 mL) and added via syringe to a mixture of phthalimide (1.38 g, 9.40 mmol) and PPh₃ (2.47 g, 9.40 mmol). The reaction mixture was allowed to stir for 10 min and then cooled to 0 °C. Once cooled, a solution of DIAD (2.48 mL, 12.5 mmol) in THF (10 mL) was added to the reaction mixture over a period of 30 min. The mixture was allowed to reach room temperature and was then stirred for 24 h. The mixture was concentrated under reduced pressure, and the residue was dissolved in Et₂O (30 mL). A solution of 2 M NaOH (15 mL) was added, and the aqueous layer was extracted with Et₂O (3×10 mL). The combined organic extracts were washed with brine (15 mL), dried with MgSO₄, filtered, and concentrated, and the residue was chromatographed on silica gel (2:3 EA/hexane) to yield the title compound as a colorless oil (1.00 g, 35%). R_f (50% EA/hex): 0.65. ¹H NMR (400 MHz, CDCl₃) δ 7.79– 7.77 (m, 2H), 7.72-7.60 (m, 3H), 7.27-7.08 (m, 2H), 7.08-6.95 (m, 4H), 6.73 (s, 1H), 5.49 (t, J = 7.8, 1H), 4.16 (dt, J = 10.0, 4.4, 1H), 3.79 (s, 2H), 3.70 (ddd, J = 13.1, 9.8, 3.5, 1H), 2.56-2.44 (m, 1H), 2.26–2.16 (m, 1H), 1.54 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 167.75, 153.57, 140.72, 137.40, 136.31, 134.14, 131.80, 128.78, 128.27, 127.87, 126.79, 126.40, 125.93, 124.50, 123.36, 80.98, 46.48, 43.20, 41.01, 28.51, 28.40.

(S)-tert-Butyl 4-Amino-6-benzyl-3,4-dihydroquinoline-1(2*H*)carboxylate (7). Compound 6 (933 mg, 1.99 mmol) was dissolved in absolute EtOH (20 mL) followed by the addition of hydrazine monohydrate (460 μ L, 5.97 mmol). The reaction mixture was stirred at room temperature for 48 h, during which time a white precipitate formed. The mixture was filtered, and the precipitate was washed with EtOH (20 mL) and the filtrate concentrated under reduced pressure. The residue was partitioned between EA (20 mL) and H₂O (10 mL), and the aqueous layer was extracted with EA (3×10 mL). Combined organic extracts were washed with brine (20 mL), dried with MgSO₄, filtered, and concentrated under reduced pressure, and the residue was chromatographed on silica gel (1:9 MeOH/DCM) to yield the title compound as a colorless oil (240 mg, 60%, 78-80% ee). R_f (10% MeOH/DCM): 0.38. ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, J = 8.5, 1H), 7.31–7.22 (m, 2H), 7.21–7.12 (m, 4H), 7.01 (dd, J = 8.5, 1.7, 1H), 3.92 (s, 2H), 3.90 (t, J = 5.8, 1H), 3.86-3.79 (m, 1H), 3.71-3.63 (m, 1H), 2.14-2.02 (m, 1H), 1.77-1.65 (m, 1H), 1.51 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 153.73, 141.13, 136.11, 135.56, 133.26, 128.87, 128.42, 127.44, 127.16, 126.02, 123.79, 80.89, 47.71, 41.57, 41.34, 33.21. Enantioselectivity determined by HPLC (Chiracel OD-RH column, 34% acetonitrile/water, 1.0 mL/min, 230 nm, 25 °C): $t_{mains} = 4.79$ min, $t_{mins} = 8.87$ min.

 $t_{\text{major}} = 4.79 \text{ min}, t_{\text{minor}} = 8.87 \text{ min}.$ General Procedure B for Compounds 8a,b. 2-(4-Nitrophenyl)-1-phenylethanone (8a). To a mixture of p-nitrophenylacetic acid (19.5 g, 108 mmol) and 150 mL of benzene was added 25 g of the 1:1 P₂O₅/Al₂O₃ mixture. The mixture was stirred overnight at reflux, and since starting material still could be seen by TLC, fresh P_2O_5/Al_2O_3 (10 g) was added and the mixture was kept under reflux and monitored by TLC until reaction completion (6 h). The mixture was then filtered, concentrated, and suspended in 200 mL of EA. The organic layer was washed with NaHCO₃ (3×50 mL) and brine ($1 \times$ 50 mL), dried over MgSO₄, and filtered. The crude residue was chromatographed on silica gel (1:1 EA/hex) to yield the title compound as a yellow solid (18 g, 70%). R_f (50% EA/hex): 0.70. ¹H NMR (500 MHz, CDCl₃) δ 8.22 (d, J = 8.6, 2H), 8.04 (d, J = 7.4, 2H), 7.64 (t, J = 7.4, 1H), 7.52 (dd, J = 10.5, 5.0, 2H), 7.46 (d, J = 8.4, 2H), 4.44 (s, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 196.01, 142.07, 136.17, 133.76, 130.67, 130.52, 128.90, 128.45, 123.76, 77.32, 77.06, 76.81, 44.95.

Naphthalen-1-yl(4-nitrophenyl)methanone (8b). 8b was synthesized according to general procedure A starting from *p*-nitrobenzoic acid (15.6 g, 93.0 mmol) and naphthalene (10.0 g, 78.0 mmol) using DCE (200 mL) as solvent to yield a yellow solid (19.0 g, 90%) as a 4:1 mixture of the title compound and the 2-naphthalene derivative, respectively. ¹H NMR (500 MHz, CDCl₃) δ 8.34–8.28 (m, 2H), 8.20–8.15 (m, 1H), 8.07 (d, *J* = 8.1, 1H), 8.02–7.98 (m, 2H), 7.95 (dd, *J* = 6.8, 2.5, 1H), 7.63–7.49 (m, 4H); ¹³C NMR (126 MHz, CDCl₃) δ 195.98, 150.15, 143.30, 134.57, 133.77, 132.60, 131.12, 130.73, 128.95, 128.60, 127.86, 126.81, 125.33, 124.23, 123.60, 77.25, 77.00, 76.75.

Procedure for 2-(4-Nitrobenzyl)naphthalene (8c). 2-Naphthalenylboronic acid (1.29 g, 7.50 mmol) and *p*-nitrobenzyl bromide (1.25 g, 5.79 mmol) were added to a microwave vessel in a 3:1 mixture of acetone/H₂O (7 mL) that was previously degassed and saturated with argon gas. PdCl₂ (17.4 mg, 1.69 mol %) and K₂CO₃ (2.40 g, 17.4 mmol) were then added. The mixture was irradiated at 110 °C for 10 min. The suspension was then concentrated, suspended in DCM (50 mL), filtered through Celite, and chromatographed on silica gel (8:92 EA/hex) to yield the title compound as a beige solid (795 mg, 52%). R_f (8% EA/hex): 0.27. ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, *J* = 8.6 Hz, 2H), 7.85–7.77 (m, 3H), 7.63 (s, 1H), 7.51–7.46 (m, 2H), 7.35 (d, *J* = 8.5 Hz, 2H), 7.27 (d, *J* = 8.2 Hz, 1H), 4.21 (s, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 148.69, 136.64, 133.59, 132.28, 129.72, 128.57, 128.25, 127.71, 127.56, 127.43, 127.21, 126.35, 125.82, 123.75, 77.39, 77.08, 76.76, 41.84.

Procedure for 2-(4-Nitrobenzylidene)-2,3-dihydro-1*H***inden-1-one (8d). To a reaction vessel containing MeOH (375 mL) was added KOH (1.91 g, 34.0 mmol). After dissolution, 1indanone (3.00 g, 22.7 mmol) was added and allowed to dissolve.** *p***-Nitrobenzaldehyde (4.12 g, 27.2 mmol) was then added to the reaction mixture and allowed to stir for 1 h. Solvent was removed under reduced pressure and the residual solid was washed with cold H₂O (50 mL) and filtered to yield a homogeneous, tan powder (5.57 g, 93%).** *R_f* **(40% EA/hex): 0.42. ¹H NMR (400 MHz, CDCl₃) δ 8.32 (d,** *J* **= 8.3, 2H), 7.94 (d,** *J* **= 7.7, 1H), 7.82 (d,** *J* **= 8.2, 2H), 7.73–7.63 (m, 2H), 7.59 (d,** *J* **= 7.5, 1H), 7.47 (t,** *J* **= 7.3, 1H), 4.10 (s, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 193.63, 149.28, 141.63, 138.43, 137.50, 135.26, 130.95, 130.81, 128.06, 126.24, 124.74, 124.08, 32.33.**

General Procedure C for Compounds 9a-d. 4-Phenethylaniline (9a). To a hydrogenation vessel was added 10% Pd/C catalyst (1.5 g) followed by the slow addition of MeOH (120 mL). 8a (6.2 g, 25.7 mmol) was dissolved in minimal MeOH and added to the vessel, followed by concentrated HCl (5.8 mL). The reaction vessel was placed on the hydrogenator under 50 psi of H₂ gas and allowed to shake for 24 h. The reaction mixture was then filtered through a pad of Celite, and solvent was removed under reduced pressure. The crude residue was extracted twice with DCM (150 mL) from 2 M NaOH (200 mL), and the combined organic layers were subsequently washed $2 \times \text{NaHCO}_3$ (100 mL), $1 \times \text{brine}$ (100 mL), dried under MgSO₄, filtered, and concentrated. The crude residue was chromatographed on silica gel (4:1 EA/hex) to yield the title compound as a beige-pinkish solid (3.70 g, 73%). R_f (75% EA/hex): 0.54. ¹H NMR (400 MHz, CDCl₃) δ 7.27–7.21 (m, 2H), 7.19–7.08 (m, 3H), 6.96–6.89 (m, 2H), 6.59–6.50 (m, 2H), 3.45 (d, J = 18.1, 2H), 2.84 (ddd, J = 8.7, 5.4, 2.2, 2H), 2.78 (ddd, J = 8.7, 5.4, 2.2, 2H); ¹³C NMR (101 MHz, CDCl₃) & 144.16, 141.88, 131.64, 129.03, 128.33, 128.11, 125.63, 115.06, 77.32, 77.00, 76.68, 38.11, 36.91.

4-(Naphthalenylmethyl)aniline (9b). 9b was synthesized according to general procedure C starting from 8b (10.0 g, 36.1 mmol) carrying over the 4:1 mixture of 1-naphthalene and 2-naphthalene intermediates, respectively, to yield a beige solid (8.00g, 95%). R_f (40% EA/hex): 0.40. ¹H NMR (500 MHz, CDCl₃) δ 7.98 (dd, J = 8.6, 4.1, 1H), 7.83–7.79 (m, 1H), 7.70 (d, J = 8.5, 1H), 7.44–7.34 (m, 3H), 7.24 (d, J = 6.9, 1H), 6.94 (d, J = 8.3, 2H), 6.54–6.52 (m, 2H), 4.30 (s, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 144.33, 137.29, 133.79, 132.04, 130.44, 129.47, 128.52, 126.97, 126.82, 125.77, 125.46, 125.40, 124.25, 115.21, 77.25, 77.00, 76.75, 38.08.

4-(Naphthalen-2-ylmethyl)aniline (9c). 9c was synthesized according to general procedure C starting from **8c** (3.60 g, 13.7 mmol) to yield a beige solid (2.30 g, 70%). R_f (40% EA/hex): 0.40. ¹H NMR (400 MHz, CDCl₃) δ 7.78–7.69 (m, 3H), 7.58 (s, 1H), 7.44–7.35 (m, 2H), 7.28 (dd, J = 8.4, 1.6 Hz, 1H), 6.98 (d, J = 8.3 Hz, 2H), 6.59–6.56 (m, 2H), 4.00 (s, 2H), 3.43 (d, J = 42.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 144.49, 139.34, 133.53, 131.93, 130.86, 129.76, 127.85, 127.57, 127.50, 127.44, 126.73, 125.79, 125.11, 115.22, 77.32, 77.00, 76.68, 41.15.

4-((2,3-Dihydro-1*H***-inden-2-yl)methyl)aniline (9d). 9d** was synthesized according to general procedure C starting from **8d** (2.13 g, 8.04 mmol) to yield a brown solid (1.70 g, 95%). R_f (5% MeOH/ DCM): 0.78. ¹H NMR (400 MHz, CDCl₃) δ 7.16 (dd, J = 8.0, 4.5, 2H), 7.14–7.08 (m, 2H), 7.01 (d, J = 8.2, 2H), 6.67 (d, J = 8.2, 2H), 3.31 (s, 2H), 2.97 (dd, J = 13.7, 5.7, 2H), 2.75–2.60 (m, 5H); ¹³C NMR (101 MHz, CDCl₃) δ 143.91, 143.34, 131.97, 129.67, 126.04, 124.48, 115.51, 41.71, 40.73, 38.86.

General Procedure D for Compounds 10a–d. 3-Bromo-*N*-(4-phenethylphenyl)propanamide (10a). Compound 9a (587 mg, 2.90 mmol) was added to a suspension of K₂CO₃ (820 mg, 5.94 mmol) in DCM (10 mL), followed by the addition of 3-bromopropionyl chloride (300 μ L, 2.99 mmol) via syringe. The resulting mixture was stirred at room temperature for 2 h and quenched by the addition of H₂O (10 mL). The mixture was extracted with DCM (25 mL), dried with MgSO₄, filtered, and concentrated to yield the title compound as a tan solid (921 mg, 93%). R_f (75% EA/hex): 0.70. ¹H NMR (400 MHz, CDCl₃) δ 7.48 (s, 1H), 7.43–7.39 (m, 2H), 7.29–7.24 (m, 2H), 7.21–7.09 (m, 5H), 3.68 (t, *J* = 6.6, 2H), 2.89 (s, 4H); ¹³C NMR (101 MHz, CDCl₃) δ 167.91, 141.51, 138.24, 135.27, 128.95, 128.41, 128.29, 125.89, 120.21, 77.32, 77.00, 76.68, 40.55, 37.82, 37.24, 27.15.

3-Bromo-N-(4-(naphthalen-1-ylmethyl)phenyl)propanamide (10b). 10b was synthesized according to general procedure D starting from 9b (1.40 g, 6.00 mmol). The crude compound was chromatographed on silica gel (4:1 EA/hex) to yield the title compound as a tan solid (1.00 g, 45%). R_f (75% EA/hex): 0.72. ¹H NMR (400 MHz, CDCl₃) δ 7.96–7.91 (m, 1H), 7.83 (dt, J = 4.1, 2.8, 1H), 7.74 (dd, J = 8.0, 4.4 Hz, 1H), 7.42–7.35 (m, 3H), 7.25 (d, J = 6.9), 7.12 (d, J = 8.5, 1H), 4.38 (s, 2H), 3.63 (t, J = 6.6, 2H), 2.85 (t, J = 6.5, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 167.92, 137.11, 136.41, 135.38, 133.89, 131.98,

129.20, 128.64, 127.25, 127.18, 125.96, 125.55, 125.50, 124.16, 120.34, 77.32, 77.00, 76.68, 40.50, 38.46, 27.11.

3-Bromo-*N***-**(**4-(naphthalen-2-ylmethyl)phenyl)propanamide** (10c). 10c was synthesized according to general procedure D starting from 9c (2.20 g, 9.00 mmol) to yield the title compound as a beige solid (3.30 g, 90%). R_f (75% EA/hex): 0.71. ¹H NMR (400 MHz, CDCl₃) δ 7.81–7.72 (m, 2H), 7.60 (s, 1H), 7.50–7.34 (m, 4H), 7.31–7.23 (m, 1H), 7.18 (d, *J* = 8.2, 2H), 7.12 (d, *J* = 8.1, 1H), 4.09 (s, 2H), 3.68 (t, *J* = 6.6, 2H), 2.90 (t, *J* = 6.5, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 167.85, 138.45, 137.43, 135.52, 133.56, 132.06, 129.57, 128.09, 127.59, 127.51, 127.00, 125.99, 125.36, 120.31, 120.20, 77.32, 77.00, 76.68, 41.48, 40.61, 27.09.

3-Bromo-*N*-(4-((2,3-dihydro-1*H*-inden-2-yl)methyl)phenyl)propanamide (10d). 10d was synthesized according to general procedure D starting from 9d (686 mg, 3.07 mmol) to yield the title compound as a fluffy, white solid (1.07 g, 98%). R_f (40% EA/hex): 0.37. ¹H NMR (400 MHz, CDCl₃) δ 7.44 (d, J = 8.2, 2H), 7.20–7.06 (m, 6H), 3.71 (t, J = 6.5, 2H), 2.98–2.63 (m, 4H), 2.77–2.60 (m, SH); ¹³C NMR (101 MHz, CDCl₃) δ 167.74, 143.10, 137.96, 135.21, 129.39, 126.11, 124.48, 120.13, 41.46, 40.93, 40.69, 38.81, 27.16.

General Procedure E for Compounds 11a–d. 1-(4-Phenethylphenyl)azetidin-2-one (11a). NaO'Bu (269 mg, 2.8 mmol) was suspended in DMF (20 mL) followed by the addition of 10a (883 mg, 2.66 mmol) previously dissolved in DMF (10 mL) via cannula. The resulting mixture was stirred at room temperature for 3 h, quenched with H₂O (10 mL), and concentrated under reduced pressure to an oil which was resuspended in EA (20 mL) and washed with H₂O (2 × 20 mL), brine (1 × 20 mL), dried with MgSO₄, filtered, concentrated, and chromatographed on silica gel (1:1 EA/hex) to yield the title compound as a white solid (457 mg, 70%). R_f (50% EA/hex): 0.49. ¹H NMR (400 MHz, CDCl₃) δ 7.29–7.23 (m, 4H), 7.21–7.09 (m, SH), 3.59 (t, J = 4.4, 2H), 3.08 (t, J = 4.5, 2H), 2.88 (s, 4H); ¹³C NMR (101 MHz, CDCl₃) δ 164.25, 141.47, 137.27, 136.55, 129.07, 128.43, 128.27, 125.89, 116.08, 77.32, 77.00, 76.68, 37.96, 37.91, 37.30, 36.00.

1-(4-(Naphthalen-1-ylmethyl)phenyl)azetidin-2-one (11b). 11b was synthesized according to general procedure E starting from **10b** (1.00 g, 2.71 mmol) to yield the title compound as a yellow solid (603 mg, 77%). R_f (50% EA/hex): 0.38. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (dd, J = 6.3, 3.0, 1H), 7.84 (dd, J = 6.1, 3.2, 1H), 7.74 (dd, J =8.3, 3.6, 1H), 7.45–7.39 (m, 3H), 7.24 (dd, J = 7.8, 6.0, 3H), 7.14 (d, J =8.4, 2H), 4.38 (s, 2H), 3.50 (t, J = 4.5, 2H), 3.02 (t, J = 4.5, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 164.21, 136.64, 136.49, 136.11, 133.88, 131.95, 129.65, 129.31, 128.62, 127.15, 125.92, 125.52, 125.47, 124.11, 116.20, 77.32, 77.00, 76.68, 38.49, 37.90, 35.97.

1-(4-(Naphthalen-2-ylmethyl)phenyl)azetidin-2-one (11c). 11c was synthesized according to general procedure E starting from **10c** (3.20 g, 8.70 mmol) to yield the title compound as a yellow solid (2.30g, 90%). R_f (50% EA/hex): 0.32. ¹H NMR (400 MHz, CDCl₃) δ 7.80–7.71 (m, 3H), 7.58 (s, 1H), 7.42 (dt, J = 13.7, 6.8, 2H), 7.26 (dd, J = 12.8, 6.0, 2H), 7.21–7.09 (m, 3H), 4.09 (s, 2H), 3.56 (t, J = 4.2, 2H), 3.06 (t, J = 4.4, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 164.32, 138.51, 136.73, 136.50, 133.54, 132.03, 129.67, 128.07, 127.57, 127.48, 127.41, 126.92, 125.97, 125.34, 116.28, 77.32, 77.00, 76.68, 41.49, 37.98, 36.00.

1-(4-((2,3-Dihydro-1*H***-inden-2-yl)methyl)phenyl)azetidin-2one (11d). 11d** was synthesized according to general procedure E starting from **10d** (1.07 g, 3.00 mmol) to yield the title compound as a light tan powder (811 mg, 98%). R_f (40% EA/hex): 0.37. ¹H NMR (400 MHz, CDCl₃) δ 7.31 (d, J = 8.3, 2H), 7.20–7.09 (m, 6H), 3.62 (t, J = 4.4, 2H), 3.11 (t, J = 4.4, 2H), 2.97 (dd, J = 14.6, 5.4, 2H), 2.78–2.61 (m, 5H); ¹³C NMR (400 MHz, CDCl₃) δ 164.26, 143.10, 137.03, 136.61, 129.47, 126.14, 124.49, 116.16, 41.56, 41.00, 38.82, 38.01, 36.07.

General Procedure F for Compounds 12a–d. 6-Phenethyl-2,3-dihydroquinolin-4(1*H*)-one (12a). Compound 11a (424 mg, 1.68 mmol) was dissolved in DCE (50 mL), and TfOH (448 μ L, 5.06 mmol) was added via syringe. The resulting mixture was stirred at room temperature for 18 h, then quenched with K₂CO₃ (1.7 g) and H₂O (86 μ L), and allowed to stir for 1 h. The mixture was filtered through a plug of MgSO₄ and concentrated under reduced pressure to yield the title compound as a yellow solid (338 mg, 80%). R_f (70% EA/hex): 0.49. ¹H NMR (400 MHz, CDCl₃) δ 7.72–7.71 (m, 1H), 7.30–7.25 (m, 2H), 7.21–7.14 (m, 3H), 7.10 (dd, J = 8.4, 2.2, 1H), 6.60 (d, J = 8.3, 1H), 4.65–3.78 (bs, 1H), 3.55 (dd, J = 7.4, 6.5, 2H), 2.91–2.78 (m, 4H), 2.69 (dd, J = 7.4, 6.5, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 193.83, 150.38, 141.62, 135.78, 131.42, 128.41, 128.30, 126.66, 125.87, 119.33, 115.89, 77.30, 76.99, 76.67, 42.45, 38.18, 37.94, 36.88.

6-(Naphthalen-1-ylmethyl)-2,3-dihydroquinolin-4(1*H***)-one (12b). 12b was synthesized according to general procedure F starting from 11b (603 mg, 2.10 mmol) to yield the title compound as a yellow solid (450 mg, 74%). R_f (50% EA/hex): 0.43. ¹H NMR (400 MHz, CDCl₃) \delta 8.00–7.95 (m, 1H), 7.84–7.79 (m, 1H), 7.77 (d, J = 1.8, 1H), 7.71 (d, J = 7.9, 1H), 7.44–7.35 (m, 3H), 7.26 (d, J = 6.5, 1H), 7.05 (dd, J = 8.4, 2.1, 1H), 6.49 (d, J = 8.4, 1H), 4.29 (s, 2H), 3.46 (t, J = 7.04, 2H), 2.63 (t, J = 6.88, 2H); ¹³C NMR (101 MHz, CDCl₃) \delta 193.78, 150.54, 136.60, 135.66, 133.89, 131.92, 130.10, 128.62, 127.24, 127.13, 127.10, 127.07, 125.92, 125.49, 124.10, 119.16, 116.13, 77.32, 77.00, 76.68, 42.28, 38.10, 38.02.**

6-(Naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1*H*)-one (12c). 12c was synthesized according to general procedure F starting from 11c (2.30 g, 8.01 mmol) to yield the title compound as a yellow solid (1.40 g, 61%). R_f (50% EA/hex): 0.43. ¹H NMR (400 MHz, CDCl3) δ 7.80–7.70 (m, 4H), 7.60 (s, 1H), 7.46–7.38 (m, 2H), 7.28 (d, J = 8.4, 1H), 7.14–7.09 (m, 1H), 6.54 (d, J = 8.4, 1H), 4.36 (s, 1H), 4.00 (s, 2H), 3.45 (t, J = 6.9, 2H), 2.64 (t, J = 6.9, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 193.80, 150.64, 138.65, 136.04, 133.48, 131.96, 130.35, 128.01, 127.50, 127.43, 127.33, 127.13, 126.75, 125.87, 125.23, 118.99, 116.22, 77.32, 77.00, 76.68, 42.16, 41.02, 38.00.

6-((2,3-Dihydro-1*H*-inden-2-yl)methyl)-2,3-dihydroquinolin-**4**(1*H*)-one (12d). 12d was synthesized according to general procedure F starting from 11d (811 mg, 2.93 mmol) to yield the title compound as a viscous yellow oil (772 mg, 95%). R_f (40% EA/ hex): 0.32. ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J = 1.9, 1H), 7.22– 7.08 (m, 5H), 6.63 (d, J = 8.3, 1H), 4.30 (br s, 1H), 3.57 (t, J = 6.9, 2H), 2.97 (dd, J = 14.2, 5.9, 2H), 2.78–2.60 (m, 7H); ¹³C NMR (101 MHz, CDCl₃) δ 193.84, 150.42, 143.12, 136.09, 131.00, 127.12, 126.06, 124.45, 119.30, 115.90, 42.47, 41.42, 40.42, 38.75, 38.22.

General Procedure G for Compounds 13a-d. (E/Z)-6-Phenethyl-2,3-dihydroquinolin-4(1H)-one Oxime (13a). Compound 12a (338 mg, 1.35 mmol) was suspended in 1:1 EtOH/H₂O followed by the addition of NH₂OH·HCl (64.5 mg, 1.47 mmol) and NaOAc·H₂O (201 mg, 1.47 mmol). The mixture was stirred at reflux overnight, after which time solvents were condensed and redissolved in EA (30 mL). The organic layer was washed with brine (10 mL), dried with MgSO₄, filtered, concentrated under reduced pressure, and chromatographed on silica gel (1:1 EA/hex) to yield the title compound as a yellow solid (235 mg, 66%). R_f (50% EA/hex): 0.51. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 2.0, 1H), 7.29–7.23 (m, 2H), 7.20-7.14 (m, 3H), 6.95 (dd, J = 8.2, 2.1, 1H), 6.57-6.52 (m, 1H), 3.30 (t, J = 6.5, 2H), 2.93 (t, J = 6.5, 2H), 2.90–2.76 (m, 4H); ^{13}C NMR (101 MHz, CDCl₃) δ 152.47, 145.29, 141.92, 131.99, 130.95, 128.42, 128.27, 125.78, 123.71, 116.68, 115.85, 77.32, 77.00, 76.68, 40.71, 38.09, 37.16, 23.58.

(*E/Z*)-6-(Naphthalen-1-ylmethyl)-2,3-dihydroquinolin-4(1*H*)one Oxime (13b). 13b was synthesized according to general procedure G starting from 12b (450 mg, 1.57 mmol) and chromatographed on silica gel (4:1 EA/hex) to yield the title compound as a yellow solid (313 mg, 66%). R_f (75% EA/hex): 0.73. ¹H NMR (400 MHz, CDCl₃) δ 8.02–7.97 (m, 1H), 7.83–7.77 (m, 1H), 7.70 (s, 2H), 7.41 (m, 3H), 7.26–7.21 (m, 1H), 6.85 (dt, *J* = 11.2, 5.6, 1H), 6.42 (d, *J* = 8.3, 1H), 4.28 (s, 2H), 3.17 (t, *J* = 6.4, 2H), 2.85 (t, *J* = 5.2, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 152.20, 145.35, 133.83, 130.94, 130.52, 129.49, 128.53, 127.02, 126.87, 125.85, 125.49, 125.41, 124.24, 124.20, 116.68, 115.98, 115.48, 77.32, 77.00, 76.68, 40.55, 38.18, 23.51.

(*E/Z*)-6-(Naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1*H*)one oxime (13c). 13c was synthesized according to general procedure G starting from 12c (522 mg, 1.81 mmol) to yield the title compound as a yellow solid (453 mg, 82%). R_f (50% EA/hex): 0.51. ¹H NMR (400 MHz, CDCl₃) δ 7.77–7.61 (m, 3H), 7.56 (d, J = 9.2, 1H), 7.42–7.32 (m, 2H), 7.26 (dd, J = 8.4, 1.3, 1H), 6.92 (dt, J = 6.8, 3.5, 1H), 6.50 (d, J = 8.3, 1H), 3.97 (s, 2H), 3.28–3.20 (m, 2H), 2.84 (t, J = 6.5, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 152.40, 145.46, 139.04, 133.58, 132.01, 131.37, 131.08, 127.99, 127.57, 127.55, 126.86, 125.83, 125.18, 124.46, 116.67, 116.06, 115.81, 77.32, 77.00, 76.68, 41.36, 40.64, 23.41.

(*E/Z*)-6-((2,3-Dihydro-1*H*-inden-2-yl)methyl)-2,3-dihydroquinolin-4(1*H*)-one oxime (13d). 13d was synthesized according to general procedure G starting from 12d (772 mg, 2.78 mmol) to yield the title compound as a yellow solid (662 mg, 81%). R_f (40% EA/hex): 0.44. ¹H NMR (400 MHz, CDCl₃) 7.63 (d, *J* = 1.8, 1H), 7.19 –7.05 (m, SH), 6.60 (dd, *J* = 21.6, 8.3, 1H), 3.30 (t, *J* = 6.5, 2H), 2.93 (dt, *J* = 13.0, 7.6, 3H), 2.76–2.59 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 152.50, 145.41, 143.38, 131.51, 131.34, 129.41, 126.08, 124.52, 124.23, 115.78, 41.57, 40.78, 40.74, 38.86, 23.45.

General Procedure H for Compounds 14a-d. 6-Phenethyl-**1,2,3,4-tetrahydroquinolin-4-amine (14a).** 10% Pd/C (50 mg) was added to a hydrogenation vessel followed by the slow addition of MeOH (10 mL). 13a (170 mg, 0.64 mmol) was dissolved in minimal MeOH and added to the vessel, followed by the addition of glacial AcOH (0.4 mL). The reaction vessel was placed on the hydrogenator under 40 psi of H₂ gas and allowed to shake for 12 h. The reaction mixture was then filtered through a pad of Celite, and solvent was removed under reduced pressure. The crude residue was resuspended in 1 M HCl (30 mL) and extracted with $3 \times EA$ (30 mL). The organic layer was washed with 3×2 M NaOH (30 mL), $1 \times$ brine (30 mL), dried under MgSO₄, filtered, and concentrated to yield the title compound as a tan oil (120 mg, 75%), which was carried to the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃) δ 8.61 (bs, 2H), 7.28-7.20 (m, 3H), 7.16 (dd, J = 13.2, 7.1, 3H), 6.82 (d, J = 8.3, 1H), 6.38 (d, J = 8.2, 1H), 4.33 (s, 1H), 3.45 (t, J = 11.2, J)1H), 3.14 (dd, J = 8.2, 4.0, 1H), 2.86-2.77 (m, 2H), 2.74-2.68 (m, 2H)2H), 2.24 (d, J = 12.2, 1H), 2.12–2.03 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) & 143.00, 141.99, 131.01, 130.37, 130.15, 128.49, 128.25, 125.77, 115.30, 115.03, 77.33, 77.01, 76.69, 47.35, 38.16, 36.96, 36.61, 26.38. ESI-MS 236.1 $[M - NH_3 + H]^+$. HPLC (gradient A): retention time = 23.79 min.

6-(Naphthalen-1-ylmethyl)-1,2,3,4-tetrahydroquinolin-4amine (14b). 14b was synthesized according to general procedure H starting from 13b (330 mg, 1.09 mmol) to yield the title compound as a tan oil (253 mg, 84%). ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J =7.9, 1H), 7.81 (d, J = 7.5, 1H), 7.69 (d, J = 8.0, 1H), 7.44–7.39 (m, 2H), 7.36 (s, 1H), 7.27–7.21 (m, 1H), 7.19 (s, 1H), 6.79 (d, J = 7.9, 1H), 6.31 (d, J = 8.2, 1H), 5.06 (bs, 3H), 4.24 (s, 2H), 4.08 (s, 1H), 3.44–3.29 (m, 1H), 3.14 (m, 1H), 2.00 (s, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 142.75, 137.30, 133.83, 132.04, 129.94, 129.58, 129.23, 128.55, 127.53, 127.04, 126.84, 125.91, 125.55, 125.44, 124.31, 115.00, 77.32, 77.00, 76.68, 46.97, 38.00, 37.00, 28.34. ESI-MS 272.1 [M – NH₃ + H]⁺. HPLC (gradient A): retention time = 31.71 min.

6-(Naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4amine (14c). 14c was synthesized according to general procedure H starting from 13c (618 mg, 2.04 mmol) to yield the title compound as a tan oil (246 mg, 86%). ¹H NMR (400 MHz, CD₃OD) δ 7.75 (dd, J = 15.5, 8.4, 3H), 7.62 (s, 1H), 7.41 (dt, J = 12.8, 6.3, 2H), 7.31 (d, J = 8.2, 1H), 7.14 (s, 1H), 7.07 (d, J = 8.0, 1H), 6.67 (d, J = 8.2, 1H), 4.42 (t, J = 4.5, 1H), 4.02 (s, 2H), 3.40–3.31 (m, 2H), 2.26–2.03 (m, 2H); ¹³C NMR (101 MHz, CD₃OD) δ 143.71, 140.64, 135.10, 133.55, 132.32, 132.09, 130.74, 128.96, 128.56, 128.49, 128.47, 127.75, 126.99, 126.32, 117.45, 49.64, 49.43, 49.21, 49.00, 48.79, 48.57, 48.36, 48.01, 42.09, 37.45, 27.37. ESI-MS 272.1 [M – NH₃ + H]⁺. HPLC (gradient A): retention time = 34.07 min.

6-((2,3-Dihydro-1*H***-inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-amine (14d).** 14d was synthesized according to general procedure H starting from 13d (662 mg, 2.26 mmol) to yield the title compound as a brown oil (527 mg, 84%). ¹H NMR (400 MHz, CDCl₃) 7.13 (ddd, J = 8.7, 7.0, 4.2, 5H), 7.05 (s, 1H), 6.87 (dd, J =8.1, 1.8, 1H), 6.46 (t, J = 6.8, 1H), 4.00 (t, J = 4.8, 1H), 3.43–3.34 (m, 1H), 3.29 (dt, J = 11.0, 5.4, 1H), 3.02–2.94 (m, 3H), 2.77–2.59 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 157.04, 150.14, 143.38, 130.14, 129.11, 128.42, 125.98, 124.44, 114.50, 46.89, 41.70, 40.74, 38.88, 37.75, 31.65. ESI-MS 262.1 [M - NH₃ + H]⁺. HPLC (gradient A): retention time = 31.39 min.

General Procedure for Compounds 15a–d). (25)-2-Amino-3-(4-hydroxy-2,6-dimethylphenyl)-*N*-(6-phenethyl-1,2,3,4-tetrahydroquinolin-4-yl)propanamide (15a). 15a was synthesized according to general procedure A from 14a (94 mg, 0.37 mmol) to yield 150 mg of crude diastereomers which were isolated by semipreparative HPLC and lyophilized to give white fluffy powders. HPLC (gradient A): retention time = 25.00 min (early), 28.19 min (late). ESI-MS 466.1 [M + Na]⁺ for both diastereomers.

(25)-2-Amino-3-(4-hydroxy-2,6-dimethylphenyl)-*N*-(6-(naphthalen-1-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)propanamide (15b). 15b was synthesized according to general procedure A from 14b (253 mg, 0.88 mmol) to yield 350 mg of a crude mixture of 1-naphthalene and 2-naphthalene derivatives as diastereomers. Only the earliest eluting peak was isolated as a pure compound by semipreparative HPLC to give a white powder. HPLC (gradient A): retention time = 31.42 min (early), 33.93 min (late). Confirmed by NMR to be the 1-naphthalene derivative. ESI-MS 502.1 $[M + Na]^+$ for both diastereomers.

(25)-2-Amino-3-(4-hydroxy-2,6-dimethylphenyl)-*N*-(6-(naph-thalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)propanamide (15c). 15c was synthesized according to general procedure A from 14c (127 mg, 0.44 mmol) to yield 200 mg of a crude mixture of diastereomers which were isolated and purified by semipreparative HPLC, then lyophilized to give white powders. HPLC (gradient A): retention time = 32.44 min (early), 34.75 min (late). ESI-MS 502.2 $[M + Na]^+$ for both diastereomers.

(25)-1-((6-((2,3-Dihydro-1*H*-inden-2-yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-amide (15d). 15d was synthesized according to general procedure A from 14d as a mixture of crude diastereomers which were isolated and purified by semipreparative HPLC and lyophilized to give a white powder of the early diastereomer and a tan powder of the late diastereomer. HPLC (gradient A): retention time = $31.09 \min$ (early), $33.76 \min$ (late). ESI-MS 492.2 [M + Na]⁺ for both diastereomers.

In Vitro Pharmacology. Cell Lines and Membrane Preparations. All tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, NY, U.S.). C6-rat glioma cells stably transfected with a rat μ (C6-MOR) or rat δ (C6-DOR) opioid receptor²⁰ and Chinese hamster ovary (CHO) cells stably expressing a human κ (CHO-KOR) opioid receptor²¹ were used for all in vitro assays. Cells were grown to confluence at 37 °C in 5% CO2 in Dulbecco's modified Eagle medium containing 10% fetal bovine serum and 5% penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with ice cold phosphate buffered saline (0.9% NaCl, 0.61 mM Na₂HPO₄, 0.38 mM KH₂PO₄, pH 7.4). Cells were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES, 150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 200g for 3 min. The cell pellet was suspended in ice-cold 50 mM Tris-HCl buffer, pH 7.4, and homogenized with a Tissue Tearor (Biospec Products, Inc., Bartlesville, OK, U.S.) for 20 s at setting 4. The homogenate was centrifuged at 20 000g for 20 min at 4 °C, and the pellet was rehomogenized in 50 mM Tris-HCl with a Tissue Tearor for 10 s at setting 2, followed by recentrifugation. The final pellet was resuspended in 50 mM Tris-HCl and frozen in aliquots at 80 °C. Protein concentration was determined via Bradford assay using bovine serum albumin as the standard.

Radioligand Binding Assays. Radioactive compounds were purchased from Perkin-Elmer (Waltham, MA, U.S.). Opioid ligandbinding assays were performed using competitive displacement of 0.2 nM [³H]diprenorphine (250 μ Ci, 1.85 TBq/mmol) by the test compound from membrane preparations containing opioid receptors. The assay mixture, containing membrane suspension (20 μ g protein/ tube) in 50 mM Tris-HCl buffer (pH 7.4), [³H]diprenorphine, and various concentrations of test peptide, was incubated at room temperature for 1 h to allow binding to reach equilibrium. The samples were rapidly filtered through Whatman GF/C filters using a Brandel harvester (Brandel, Gaithersburg, MD, U.S.) and washed three times with 50 mM Tris-HCl buffer. The radioactivity retained on dried filters was determined by liquid scintillation counting after saturation with EcoLume liquid scintillation cocktail in a Wallac 1450 MicroBeta (Perkin-Elmer, Waltham, MA, U.S.). Nonspecific binding was determined using 10 μ M naloxone. K_i values were calculated using nonlinear regression analysis to fit a logistic equation to the competition data using GraphPad Prism, version 5.01, for Windows (GraphPad Software Inc., La Jolla, CA). The results presented are the mean \pm standard error from at least three separate assays performed in duplicate.

Stimulation of $[^{35}S]$ GTP γS Binding. Agonist stimulation of ³⁵S]guanosine 5'-O-[y-thio]triphosphate (³⁵S]GTPyS, 1250 Ci, 46.2 TBq/mmol) binding was measured as described previously.²² Briefly, membranes (10–20 μ g of protein/tube) were incubated 1 h at room temperature in GTPyS buffer (50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl₂, pH 7.4) containing 0.1 nM $[^{35}S]$ GTP γ S, 30 μ M guanosine diphosphate (GDP), and varying concentrations of test peptides. Peptide stimulation of $[^{35}S]GTP\gamma S$ was compared with 10 μ M standard compounds [D-Ala², N-MePhe⁴, Gly-ol]enkephalin (DAMGO) at MOR, D-Pen^{2,5}-enkephalin (DPDPE) at DOR, or U69,593 at KOR. The reaction was terminated by rapidly filtering through GF/C filters and washing 10 times with GTP_γS buffer, and retained radioactivity was measured as described above. The results presented are the mean \pm standard error from at least three separate assays performed in duplicate; maximal stimulation was determined using nonlinear regression analysis with GraphPad Prism (GraphPad Software Inc., La Jolla, CA).

In Vivo Pharmacology. Animals. Adult male C57BL/6 mice weighing between 20 and 30 g at 8–16 weeks old were used for the current experiments (obtained from Jackson Laboratories (Bar Harbor, ME), Harlan (Indianapolis, IN), or bred in-house). Mice were group-housed and had free access to food and water at all times. Experiments were conducted in the housing room, which was maintained on a 12 h light/dark cycle (with lights on at 0700). Each mouse was used only once and experiments were conducted between 11 a.m. and 4 p.m. Studies were performed in accordance with the University of Michigan Committee on the Use and Care of Animals and the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011 publication).

Antinociception. The antinociceptive effects of 1(4R) and morphine were evaluated in the warm water tail withdrawal assay using a cumulative dosing procedure.²³ To determine tail withdrawal latencies, each mouse was placed briefly into a plastic, cylindrical restrainer and 2-3 cm of the tail tip was placed into a water bath maintained at 50 $^\circ\text{C}.$ The latency to withdraw the tail was recorded with a maximum cutoff time of 20 s. If the mouse did not remove its tail by the cutoff time, the experimenter removed its tail from the water to prevent tissue damage. Each animal received an injection of saline (intraperitoneal, ip) and then 30 min later, the baseline withdrawal latencies were recorded and ranged between 3 and 6 s. Following baseline determinations, three increasing doses (1, 2.2, and 6.8 mg/kg) of 1(4R) were given at 30 min intervals to provide final doses of 1, 3.2, and 10 mg/kg. Thirty minutes after each injection, the tail withdrawal latency was measured as described above. To confirm that 1(4R) was acting at opioid receptors, the cumulative dose response was repeated over the doses 3.2, 10, and 32 mg/kg following a 30 min pretreatment with 1 mg/kg naltrexone (ip). To determine the time-course of antinociceptive action the tail-withdrawal test was performed at varying times following administration of morphine (10 mg/kg, ip) or 1(4R) (10 mg/kg, ip).

AUTHOR INFORMATION

Corresponding Author

*Phone: (734) 764-8117. E-mail: him@umich.edu.

Notes The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was funded by NIH Grants DA003910 (H.I.M.) and DA004087 (J.R.T.). J.P.A. was supported by NIH Predoctoral Training Grants DA007281 and GM007767. L.Y. was supported by NIH Postdoctoral Training Grant DA007267. A.A.H. was supported by NIH Predoctoral Training Grant DA007281 and by a University of Michigan College of Pharmacy Lyons Fellowship.

ABBREVIATIONS USED

MOR, μ opioid receptor; DOR, δ opioid receptor; KOR, κ opioid receptor; Aic, 2-aminoindane-2-carboxylic acid; Pen, penicillamine; cSEtS, cyclization through an ethylene dithioether linkage; cSS, cyclization through a disulfide linkage; THQ, tetrahydroquinoline; CHO, Chinese hamster ovary; GTP γ S, guanosine 5'-O-[γ -thio]triphosphate; WWTW, warm water tail withdrawal; TM, transmembrane; 1-Nal, 1-naphthylalanine; 2-Nal, 2-naphthylalanine; (Boc)₂O, di-tertbutyl dicarbonate; DIEA, N,N-diisopropylethylamine; EA, ethyl acetate; hex, hexanes; DIAD, diisopropyl azodicarboxylate; TfOH, triffic acid; PyBOP, benzotriazol-1-yloxytripyrrolidino-phosphonium hexafluorophosphate; HOBt-Cl, 6-chlorohydroxybenzotriazole; Boc-Dmt, tert-butyloxycarbonyl-protected 2,6-dimethyltyrosine

REFERENCES

(1) Morphy, R.; Kay, C.; Rankovic, Z. From Magic Bullets to Designed Multiple Ligands. Res. Focus Rev. 2004, 9, 641-652.

(2) Morphy, R.; Rankovic, Z. Designing Multiple Ligands— Medicinal Chemistry Strategies and Challenges. *Curr. Pharm. Des.* **2009**, *15*, 587–600.

(3) Morphy, R.; Rankovic, Z. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm. *J. Med. Chem.* **2005**, *48*, 6523–6543.

(4) Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. Selective Blockage of the Delta Opioid Receptors Prevents the Development of Morphine Tolerance and Dependence in Mice. *J. Pharmacol. Exp. Ther.* **1991**, 258, 299–303.

(5) Fundytus, M. E.; Schiller, P. W.; Shapiro, M.; Weltrowska, G.; Coderre, T. J. Attenuation of Morphine Tolerance and Dependence with the Highly Selective Delta Opioid Receptor Antagonist TIPP(psi). *Eur. J. Pharmacol.* **1995**, *286*, 105–108.

(6) Hepburn, M. J.; Little, P. J.; Gringas, J.; Khun, C. M. Differential Effects of Naltrindole on Morphine-Induced Tolerance and Physical Dependence in Rate. *J. Pharmacol. Exp. Ther.* **1997**, *281*, 1350–1356.

(7) Purington, L. C.; Sobczyk-Kojiro, K.; Pogozheva, I. D.; Traynor, J. R.; Mosberg, H. I. Development and in Vitro Characterization of a Novel Bifunctional mu-Agonist/delta-Antagonist Opioid Tetrapeptide. *ACS Chem. Biol.* **2011**, *6*, 1375–1381.

(8) Anand, J. P.; Purington, L. C.; Pogozheva, I. D.; Traynor, J. R.; Mosberg, H. I. Modulation of Opioid Receptor Ligand Affinity and Efficacy Using Active and Inactive State Receptor Models. *Chem. Biol. Drug Des.* **2012**, *80*, 763–770.

(9) Schiller, P. W.; Fundytus, M. E.; Merovitz, L.; Weltrowska, G.; Nguyen, T. M.; Lemieux, C.; Chung, N. N.; Coderre, T. J. The Opioid mu Agonist/delta Antagonist DIPP-NH(2)[Psi] Produces a Potent Analgesic Effect, No Physical Dependence, and Less Tolerance than Morphine in Rats. J. Med. Chem. **1999**, 42, 3520–3526.

(10) Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic Pharmacophore: Conversion of a Potent delta-Opioid Receptor Antagonist into a Potent delta Agonist and Ligands with Mixed Properties. J. Med. Chem. 2002, 45, 713–720.

(11) Balboni, G.; Salvadori, S.; Trapella, C.; Knapp, B. I.; Bidlack, J. M.; Lazarus, L. H.; Peng, X.; Neumeyer, J. L. Evolution of the

Bifunctional Lead mu Agonist/delta Antagonist Containing the Dmt-Tic Opioid Pharmacophore. ACS Chem. Neurosci. **2010**, 1, 155–164. (12) Ananthan, S.; Saini, S. K.; Dersch, C. M.; Xu, H.; McGlinchey, N.; Giuvelis, D.; Bilsky, E. J.; Rothman, R. B. 14-Alkoxy- and 14-Acyloxypyridomorphinans: μ Agonist/ δ Antagonist Opioid Analgesics with Diminished Tolerance and Dependence Side Effects. J. Med. Chem. **2012**, 55, 8350–8363.

(13) Li, Y.; Lefever, M. R.; Muthu, D.; Bidlack, J. M.; Bilsky, E. J.; Polt, R. Opioid Glycopeptide Analgesics Derived from Endogenous Enkephalins and Endorphins. *Future Med. Chem.* **2012**, *4*, 205–226.

(14) El-Andaloussi, S.; Holm, T.; Langel, U. Cell-Penetrating Peptides: Mechanisms and Applications. *Curr. Pharm. Des.* **2005**, *11*, 3597–3611.

(15) Egleton, R. D.; Davis, T. P. Development of Neuropeptide Drugs That Cross the Blood–Brain Barrier. *NeuroRx* 2005, 2, 44–53. (16) Wang, C.; McFadyen, I. J.; Traynor, J. R.; Mosberg, H. I. Design of a High Affinity Peptidomimetic Opioid Agonist from Peptide

Pharmacophore Models. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2685–2688. (17) Mathre, D. J.; Thompson, A. S.; Douglas, A. W.; Hoogsteen, K.; Carroll, J. D.; Corey, E. G.; Grabowski, E. J. Practical Process for the Preparation of Tetrahydro-1-methyl-3,3-diphenyl-1*H*,3*H*-pyrrolo[1,2-*c*][1,3,2]oxazaborole-borane. A Highly Enantioselective Stoichiometric and Catalytic Reducing Agent. *J. Org. Chem.* **1993**, *58*, 2880–2888.

(18) Ohn, V.; Maillard, M.; Tucker, J.; Jagodzinska, B.; Brogley, L.; Tung, J.; Shah, N.; Neitz, J. R. Substituted Hydroxyethylamine Aspartyl Protease Inhibitors. Patent Application WO2005/87752 A2, 2005.

(19) Mitsunobu, O.; Wada, M.; Sano, T. J. Stereospecific and Stereoselective Reactions. I. Preparation of Amines from Alcohols. J. Am. Chem. Soc. **1972**, *94*, 679–680.

(20) Lee, K. O.; Akil, H.; Woods, J. H.; Traynor, J. R. Differential Binding Properties of Oripavines at Cloned Mu- and Delta-Opioid Receptors. *Eur. J. Pharmacol.* **1999**, *378*, 323–330.

(21) Husbands, S. M.; Neilan, C. L.; Broadbear, J.; Grundt, P.; Breeden, S.; Aceto, M. D.; Woods, J. H.; Lewis, J. W.; Traynor, J. R. BU74, a Complex Oripavine Derivative with Potent Kappa Opioid Receptor Agonism and Delayed Opioid Antagonism. *Eur. J. Pharmacol.* **2005**, *509*, 117–135.

(22) Traynor, J. R.; Nahorski, S. R. Modulation by Mu-Opioid Agonists of Guanosine-5'-O(3-[³⁵S]thio)triphosphate Binding to Membranes from Human Neuroblastoma SHY5Y Cells. *Mol. Pharmacol.* **1995**, 47, 848–854.

(23) Lamberts, J. T.; Jutkiewicz, E. M.; Mortensen, R. M.; Traynor, J. R. Mu-Opioid Receptor Coupling to $G\alpha(o)$ Plays an Important Role in Opioid Antinociception. *Neuropsychopharmacology* **2011**, *36*, 2041–2053.

(24) Purington, L. C.; Pogozheva, I. D.; Traynor, J. R.; Mosberg, H. I. Pentapeptides Displaying mu Opioid Receptor Agonist and delta Opioid Receptor Partial Agonist/Antagonist Properties. *J. Med. Chem.* **2009**, *52*, 7724–7731.

(25) Hajipour, A. R.; Zarei, A.; Khazdooz, L.; Ruoho, A. E. Simple and Efficient Procedure for the Friedel–Crafts Acylation of Aromatic Compounds with Carboxylic Acids in the Presence of P_2O_5/Al_2O_3 Under Heterogeneous Conditions. *Synth. Commun.* **2009**, *39*, 2702–2722.

(26) Bandgar, B. P.; Bettigeri, S. V.; Phopase, J. J. Palladium Catalyzed Ligand-Free Suzuki Cross-Coupling Reactions of Benzylic Halides with Aryl Boronic Acids under Mild Conditions. *Tetrahedron Lett.* **2004**, 45, 6959–6962.

(27) Schmidt, R. G.; Bayburt, E. K.; Latshaw, S. P.; Koenig, J. R.; Daanen, J. F.; McDonald, H. A.; Bianchi, B. R.; Zhong, C.; Joshi, S.; Honore, P.; Marsh, K. C.; Lee, C. H.; Faltynek, C. R.; Gomtsyan, A. L. Chroman and Tetrahydroquinoline Ureas As Potent TRPV1 Antagonists. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 1338–1341.

(28) Volkow, N. D. Opioid–Dopamine Interactions: Implications for Substance Use Disorders and Their Treatment. *Biol. Psychiatry* **2010**, *68*, 685–686.

(29) Bowen, C. A.; Negus, S. S.; Zong, R.; Neumeyer, J. L.; Bidlack, J. M.; Mello, N. K. Effects of Mixed-Action kappa/mu Opioids on

Journal of Medicinal Chemistry

Cocaine Self-Administration and Cocaine Discrimination by Rhesus Monkeys. *Neuropsychopharmacology* **2003**, *28*, 1125–1139.

(30) Dietis, N.; Guerrini, R.; Calo, G.; Salvadori, S.; Rowbotham, D. J.; Lambert, D. G. Simultaneous Targeting of Multiple Opioid Receptors: A Strategy To Improve Side-Effect Profile. *Br. J. Anaesth.* **2009**, *103*, 38–49.

(31) Horan, P. J.; Mattia, A.; Bilsky, E. J.; Weber, S.; Davis, T. P.; Yamamura, H. I.; Malatynska, E.; Appleyard, S. M.; Slaninova, J.; Misicka, A.; Lipkowski, A. W.; Hruby, V. J.; Porreca, F. Antinociceptive Profile of Biphalin, a Dimeric Enkephalin Analog. *J. Pharmacol. Exp. Ther.* **1993**, *265*, 1446–1454.

(32) Li, Y.; Lefever, M. R.; Muthu, D.; Bidlack, J. M.; Bilsky, E J.; Polt, R. Opioid Glycopeptide Analgesics Derived from Endogenous Enkephalins and Endorphins. *Future Med. Chem.* **2012**, *4*, 205–226.

(33) Lee, Y. S.; Kulkarani, V.; Cowell, S. M.; Ma, S.; Davis, P.; Hanlon, K. E.; Vanderah, T. W.; Lai, J.; Porreca, F.; Vardanyan, R.; Hruby, V. J. Development of Potent μ and δ Opioid Agonists with High Lipophilicity. *J. Med. Chem.* **2011**, *54*, 382–386.

(34) Lowery, J. J.; Raymond, T. J.; Giuvelis, D.; Bidlack, J. M.; Polt, R.; Bilsky, E J. In Vivo Characterization of MMP-2200, a Mixed δ/μ Opioid Agonist, In Mice. J. Pharmacol. Exp. Ther. **2011**, 336, 767–778.

(35) Jiang, Q.; Mosberg, H. I.; Porreca, F. Modulation of the Potency and Efficacy of mu-Mediated Antinociception by delta Agonists in the Mouse. J. Pharmacol. Exp. Ther. **1990**, 254, 683–689.

(36) Neilan, C. L.; Husbands, S. M.; Breeden, S.; Ko, M. C.; Aceto, M. D.; Lewis, J. W.; Woods, J. H.; Traynor, J. R. Characterization of the Complex Morphinan Derivative BU72 as a High Efficacy, Long-Lasting mu-Opioid Receptor Agonist. *Eur. J. Pharmacol.* **2004**, *499*, 107–116.